1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Bigelizumab Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 160 mg/1 mL
  • 1.3.3 320 mg/2 mL
• 1.4 Market Analysis by Sales Channels
  • 1.4.1 Overview: Global Bigelizumab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
  • 1.4.2 Hospital
  • 1.4.3 Retail
  • 1.4.4 Online
• 1.5 Market Analysis by Route of Administration
  • 1.5.1 Overview: Global Bigelizumab Consumption Value by Route of Administration: 2021 Versus 2025 Versus 2032
  • 1.5.2 Subcutaneous Injection
  • 1.5.3 Intravenous Infusion
• 1.6 Market Analysis by Combination Therapy
  • 1.6.1 Overview: Global Bigelizumab Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
  • 1.6.2 Combination with Methotrexate
  • 1.6.3 Combination with Nonsteroidal Anti-Inflammatory Drugs
• 1.7 Market Analysis by Application
  • 1.7.1 Overview: Global Bigelizumab Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.7.2 Treatment Of Psoriasis
  • 1.7.3 Treatment Of Psoriatic Arthritis
  • 1.7.4 Treatment Of Autoimmune Inflammatory Diseases
  • 1.7.5 Others
• 1.8 Global Bigelizumab Market Size & Forecast
  • 1.8.1 Global Bigelizumab Consumption Value (2021 & 2025 & 2032)
  • 1.8.2 Global Bigelizumab Sales Quantity (2021-2032)
  • 1.8.3 Global Bigelizumab Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 UCB Pharma S.A
  • 2.1.1 UCB Pharma S.A Details
  • 2.1.2 UCB Pharma S.A Major Business
  • 2.1.3 UCB Pharma S.A Bigelizumab Product and Services
  • 2.1.4 UCB Pharma S.A Bigelizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 UCB Pharma S.A Recent Developments/Updates

3 Competitive Environment: Bigelizumab by Manufacturer

• 3.1 Global Bigelizumab Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Bigelizumab Revenue by Manufacturer (2021-2026)
• 3.3 Global Bigelizumab Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Bigelizumab by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Bigelizumab Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Bigelizumab Manufacturer Market Share in 2025
• 3.5 Bigelizumab Market: Overall Company Footprint Analysis
  • 3.5.1 Bigelizumab Market: Region Footprint
  • 3.5.2 Bigelizumab Market: Company Product Type Footprint
  • 3.5.3 Bigelizumab Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Bigelizumab Market Size by Region
  • 4.1.1 Global Bigelizumab Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Bigelizumab Consumption Value by Region (2021-2032)
  • 4.1.3 Global Bigelizumab Average Price by Region (2021-2032)
• 4.2 North America Bigelizumab Consumption Value (2021-2032)
• 4.3 Europe Bigelizumab Consumption Value (2021-2032)
• 4.4 Asia-Pacific Bigelizumab Consumption Value (2021-2032)
• 4.5 South America Bigelizumab Consumption Value (2021-2032)
• 4.6 Middle East & Africa Bigelizumab Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Bigelizumab Sales Quantity by Type (2021-2032)
• 5.2 Global Bigelizumab Consumption Value by Type (2021-2032)
• 5.3 Global Bigelizumab Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Bigelizumab Sales Quantity by Application (2021-2032)
• 6.2 Global Bigelizumab Consumption Value by Application (2021-2032)
• 6.3 Global Bigelizumab Average Price by Application (2021-2032)

7 North America

• 7.1 North America Bigelizumab Sales Quantity by Type (2021-2032)
• 7.2 North America Bigelizumab Sales Quantity by Application (2021-2032)
• 7.3 North America Bigelizumab Market Size by Country
  • 7.3.1 North America Bigelizumab Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Bigelizumab Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Bigelizumab Sales Quantity by Type (2021-2032)
• 8.2 Europe Bigelizumab Sales Quantity by Application (2021-2032)
• 8.3 Europe Bigelizumab Market Size by Country
  • 8.3.1 Europe Bigelizumab Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Bigelizumab Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Bigelizumab Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Bigelizumab Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Bigelizumab Market Size by Region
  • 9.3.1 Asia-Pacific Bigelizumab Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Bigelizumab Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Bigelizumab Sales Quantity by Type (2021-2032)
• 10.2 South America Bigelizumab Sales Quantity by Application (2021-2032)
• 10.3 South America Bigelizumab Market Size by Country
  • 10.3.1 South America Bigelizumab Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Bigelizumab Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Bigelizumab Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Bigelizumab Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Bigelizumab Market Size by Country
  • 11.3.1 Middle East & Africa Bigelizumab Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Bigelizumab Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Bigelizumab Market Drivers
• 12.2 Bigelizumab Market Restraints
• 12.3 Bigelizumab Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Bigelizumab and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Bigelizumab
• 13.3 Bigelizumab Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Bigelizumab Typical Distributors
• 14.3 Bigelizumab Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Bigelizumab market size was valued at US$ 268 million in 2025 and is forecast to a readjusted size of US$ 975 million by 2032 with a CAGR of 12.4% during review period.
Bigelizumab is a humanized anti-interleukin-17A monoclonal antibody designed for the treatment of autoimmune and inflammatory diseases. It selectively binds to IL‑17A with high affinity, blocks its interaction with cellular receptors, and inhibits downstream pro‑inflammatory signaling pathways, thereby reducing inflammation, tissue damage, and disease activity. With favorable safety and pharmacokinetic properties, it is being investigated in clinical trials mainly for moderate to severe psoriasis, psoriatic arthritis, and other IL‑17‑mediated disorders, aiming to provide a safe and effective biological option for patients with inadequate response to conventional therapies.In 2025, global Bigelizumab production reached approximately 1.2–1.5 million units.
Bigelizumab, a fully human monoclonal antibody targeting IL-17A, operates within a rapidly expanding market for autoimmune disease biologics, driven by rising global clinical demand for psoriasis, psoriatic arthritis, and other related indications. While the IL-17 inhibitor segment is highly competitive with established therapies, Bigelizumab holds differentiation potential through its high binding affinity, favorable pharmacokinetics, and strong safety profile. Its future commercial success will depend on clinical efficacy, approved indications, reimbursement access, pricing strategy, and commercial execution, amid intensifying competition from existing IL-17 inhibitors, dual-targeted agents, and rapidly emerging domestic biologic alternatives.
This report is a detailed and comprehensive analysis for global Bigelizumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Bigelizumab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Bigelizumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Bigelizumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Bigelizumab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Bigelizumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Bigelizumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include UCB Pharma S.A, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Bigelizumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
160 mg/1 mL
320 mg/2 mL
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Route of Administration
Subcutaneous Injection
Intravenous Infusion
Market segment by Combination Therapy
Combination with Methotrexate
Combination with Nonsteroidal Anti-Inflammatory Drugs
Market segment by Application
Treatment Of Psoriasis
Treatment Of Psoriatic Arthritis
Treatment Of Autoimmune Inflammatory Diseases
Others
Major players covered
UCB Pharma S.A
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Bigelizumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Bigelizumab, with price, sales quantity, revenue, and global market share of Bigelizumab from 2021 to 2026.
Chapter 3, the Bigelizumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Bigelizumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Bigelizumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Bigelizumab.
Chapter 14 and 15, to describe Bigelizumab sales channel, distributors, customers, research findings and conclusion.